Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 

Access Accelerated – joint initiative to fight non-communicable diseases

At the World Economic Forum in Davos, Switzerland, 22 leading global pharma companies, including Merck KGaA, Darmstadt, Germany, announced plans to launch a worldwide initiative called Access Accelerated.

Our collaborations in Silicon Valley

By cooperating with U.S. software developer Palantir Technologies and Stanford University as well as entering into agreements with three further partners in the United States, we are capturing new business opportunities. We are thus strengthening our position as an innovation-based science and technology company.

Publication of Q3 2016 Results

“We had a good third quarter and are lifting our guidance for the full year. We have made good progress with the execution of our strategy. We have advanced our pharmaceutical pipeline and are realizing the cost synergies from the acquisition of Sigma-Aldrich faster than planned. In the course of the year, we have lowered our debt from the acquisition by € 1 billion.” Stefan Oschmann, CEO and Chairman of the Executive Board

 

Media Services for the US and Canada

Access Accelerated – joint initiative to fight non-communicable diseases
Access Accelerated – joint initiative to fight non-communicable diseases
At the World Economic Forum in Davos, Switzerland, 22 leading global pharma companies, including Merck KGaA, Darmstadt, Germany, announced plans to launch a worldwide initiative called Access Accelerated. The initiative aims to improve the prevention and treatment of non-communicable diseases (NCDs) in low- and middle-income countries. NCDs include, for example, cancer, diabetes, cardiovascular and chronic respiratory diseases.
 
Stefan Oschmann, Chairman of the Executive Board and CEO
New business opportunities in the U.S.
„As a key provider to the digital industry, we already have good ties to technology companies in Silicon Valley. Over the past two weeks, we have expanded our presence here and in other parts of the U.S. by entering into new partnerships and pursuing further business opportunities.“
Stefan Oschmann, Chairman of the Executive Board and CEO
 
Merck KGaA, Darmstadt, Germany, Licenses Four Oncology Research and Development Programs from Vertex and Becomes a Leader in DNA Damage and Repair
Merck KGaA, Darmstadt, Germany, Licenses Four Oncology Research and Development Programs from Vertex and Becomes a Leader in DNA Damage and Repair
Darmstadt, Germany, January 11, 2017 – Merck KGaA, Darmstadt, Germany today announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Incorporated, Boston, USA, for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.
 
 
top

DOWNLOAD LIBRARY

Download Library
Download images, Media Kits and other material from our media download library

CALENDAR OF EVENTS

Calendar of Events
Find and register for upcoming events

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 

FOR MEDIA INQUIRIES, CONTACT

Media Team
POSTAL ADDRESS 
Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250 
64293 Darmstadt 
Germany
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138
 

GENERAL INQUIRIES

Communications Center
Tel.: +49 6151 72-0
Fax: +49 6151 72-2000
 

CURRENT FINANCIAL REPORT

Current Financial Report
Merck KGaA, Darmstadt, Germany on Facebook
Twitter